Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561521 | 1.00 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL28332254 | 0.89 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL7019874 | 0.87 | PNMT (0.65) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL1558102 | 0.83 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL30053511 | 0.83 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL383577 | 0.78 | PNMT (0.74) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL26640744 | 0.78 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| Hydrochloric Acid SCHEMBL1786988 | 0.76 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL12827583 | 0.76 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL429310 | 0.74 | MAPT (0.57) | PNMTADRA2AADRA2BADRA2CTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | claimed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3661918-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2021-10-14 | — | — | US | disclosed |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | RECURIUM IP HOLDINGS, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3661918-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D]PYRIMIDIN -3 - ONE ANALOGS | Recurium IP Holdings, LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2020-05-21 | — | — | US | disclosed |
| CN-111094253-A | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019028008-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS | Zeno Royalties & Milestones, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PNMT 112/4885ADRA2A 448/4885ADRA2B 381/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PNMT 12/4885ADRA2A 135/4885ADRA2B 140/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PNMT 112/4885ADRA2A 448/4885ADRA2B 381/4885 |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | PNMT 4734/4885ADRA2A 2905/4885ADRA2B 2405/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | PNMT 26/4885ADRA2A 266/4885ADRA2B 273/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PNMT 112/4885ADRA2A 448/4885ADRA2B 381/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | PNMT 36/4885ADRA2A 298/4885ADRA2B 221/4885 |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | PNMT 4734/4885ADRA2A 2905/4885ADRA2B 2405/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | PNMT 3057/4885ADRA2A 1911/4885ADRA2B 2313/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PNMT 112/4885ADRA2A 448/4885ADRA2B 381/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | PNMT 36/4885ADRA2A 298/4885ADRA2B 221/4885 |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | MKI67, BRCA1, CCND1 | PNMT 4761/4885ADRA2A 2730/4885ADRA2B 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.